Clinical Trial Detail

NCT ID NCT02425306
Title Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Craig L Slingluff, Jr
Indications

melanoma

Therapies

Cyclophosphamide

6MHP vaccine

Poly ICLC

Age Groups: adult

No variant requirements are available.